Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC) Meeting Abstract
| Authors: | Azad, A.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Rathkopf, D.; Runcie, K.; Zhang, T.; Gotto, G.; Merseburger, A. S.; Dos Santos, A.; Shopeju, S.; Bhaumik, A.; Mundle, S. D.; McCarthy, S.; Agarwal, N. |
| Abstract Title: | Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC) |
| Meeting Title: | 2025 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 5 Suppl. |
| Meeting Dates: | 2025 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-10 |
| Language: | English |
| ACCESSION: | WOS:001454759900015 |
| DOI: | 10.1200/JCO.2025.43.5_suppl.147 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 147 -- Source: Wos |
